EN | UA
EN | UA

Help Support

Back

Rapidly improved patient-reported outcomes with the use of Upadacitinib

Atopic dermatitis Atopic dermatitis
Atopic dermatitis Atopic dermatitis

What's new?

Once-daily use of Upadacitinib 15 mg or 30 mg exhibits superior symptom relief and enhanced quality of life, with rapid and sustained improvements observed across various patient-reported outcomes (such as pain, itching, etc.), starting within 1–2 weeks.

The integrated data from the two clinical trials suggested that Upadacitinib monotherapy rapidly and effectively improved patient-reported outcomes (PROs) in adults and adolescents with AD of moderate-to-severe intensity.

The analysis performed by Eric L. Simpson et al. included 1683 patients (557 receiving Upadacitinib 15 mg, 567 receiving Upadacitinib 30 mg, and 559 receiving placebo given once daily).

A significantly higher proportion of patients on Upadacitinib felt relief from itch (defined as a ≥4-point improvement on the Worst Pruritus Numerical Rating Scale [WP-NRS]) by week 1, with response rates maintained through week 16. Similar improvements were observed in PROs related to skin pain/symptoms, sleep, routine chores, quality of life, emotional state, mental health and patient opinions of disease severity and treatment efficacy.

These improvements were apparent early in the treatment process, with responses typically improving rapidly within 1 to 2 weeks, increasing further by weeks 4–6, which continues through the 16-week assessment period. Overall, the findings suggest that Upadacitinib holds promise in rapidly and effectively improving PROs in individuals with AD.

Source:

Dermatology and Therapy

Article:

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Authors:

Eric L. Simpson et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: